Atiq, M. O., Page, A., Catenacci, M., Patnaik, A., Paner, G. P., Eggener, S. E., Szmulewitz, R. Z. (2026). High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps415